- Home
- BSEM vs TCRX Comparison
BSEM vs TCRX Comparison
Compare BSEM & TCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BSEM | TCRX |
|---|---|---|
| Founded | N/A | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 59.6M | 49.4M |
| IPO Year | 2026 | 2021 |
Fundamental Metrics
Financial Performance| Metric | BSEM | TCRX |
|---|---|---|
| Price | $3.68 | $0.73 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | 117.1K | ★ 302.2K |
| Earning Date | N/A | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 12.28 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $10,325,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $19.81 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 266.65 |
| 52 Week Low | $2.25 | $0.72 |
| 52 Week High | $4.66 | $2.57 |
Technical Indicators
Market Signals| Indicator | BSEM | TCRX |
|---|---|---|
| Relative Strength Index (RSI) | 44.18 | 38.53 |
| Support Level | $2.25 | N/A |
| Resistance Level | $3.99 | $0.82 |
| Average True Range (ATR) | 0.41 | 0.04 |
| MACD | 0.03 | 0.00 |
| Stochastic Oscillator | 73.67 | 6.40 |
Price Performance
Historical ComparisonAbout BSEM BioStem Technologies Inc. Common Stock
BioStem Technologies Inc is a regenerative biotechnology company focused on harnessing elements of perinatal tissue and the body's innate biology to repair or reverse damage caused by a broad range of degenerative diseases. The company develops, manufactures, and sells tissue allografts for the wound care market with a focus on the treatment of diabetic, pressure, and venous ulcers. Utilizing its proprietary BioRetain processing method, it manufactures perinatal tissue allografts. The company offers a comprehensive portfolio of high-quality brands that are trademarked and include VENDAJE AC, AmnioWrap2, and Others. The company generates key revenue from VENDAJE AC.
About TCRX TScan Therapeutics Inc.
TScan Therapeutics Inc is a fully integrated clinical-stage biotechnology company focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell, or TCR-T, therapies for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.